NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results